Expression, purification, refolding, and characterization of recombinant human soluble-Fas ligand from Escherichia coli

Enzyme and Microbial Technology

Volumn 36, Issue 4, 2005, Pages 527-534

  Sun, Kuang Hui ^a   Sun, Guang Huan ^b   Tsai, Chang Youh ^c   Wang, Hsiao Hsien ^d   Chung I, Chang ^e   Lin, Guang ^f   Lin, Wen Wen ^f   Tang, Shye Jye ^f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHENG HSIN REHABILITATION MEDICAL CENTER   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Fas ligand; Refolding

Indexed keywords

CELLS; CHEMOTHERAPY; ESCHERICHIA COLI; NICKEL; OLIGOMERS; TUMORS;

APOPTOSIS; FAS-BEARING CELLS; REFOLDING PROCESS; STABLE TRIMERS;

PROTEINS;

FAS LIGAND; NICKEL; RESIN; UREA;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; APOPTOSIS; ARTICLE; ESCHERICHIA COLI; GEL FILTRATION; GENE; GLIA CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION; RAT; T LYMPHOCYTE; WESTERN BLOTTING;

ESCHERICHIA COLI;

EID: 13244281956     PISSN: 01410229     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.enzmictec.2004.11.013     Document Type: Article

References (39)

1. T. Suda, T. Takahashi, P. Golstein, and S. Nagata Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family Cell 75 1993 1169 1178
2. D.R. Green, and C.F. Ware Fas-ligand: privilege and peril Proc Natl Acad Sci U S A 94 1997 5986 5990
3. T.S. Griffith, T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson Fas ligand-induced apoptosis as a mechanism of immune privilege Science 270 1995 1189 1192
4. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, P.M. Schreier, and L.E. French Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumor immune escape Science 274 1996 1363 1366
5. S.M. Kang, D.B. Schneider, Z. Lin, D. Hanahan, D.A. Dichek, and P.G. Stock Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction Nat Med 3 1997 738 743
6. J. O'Connell, A. Houston, M.W. Bennett, G.C. O'Sullivn, and F. Shanahan Immune privilege or inflammation? Insights into the Fas ligand enigma Nat Med 7 2001 271 274
7. J.J. Chen, Y. Sun, and G.J. Nabel Regulation of the pro-inflammatory effects of Fas ligand (CD95L) Science 282 1998 1714 1717
8. S.T. Ju, D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, and D.H. Sherr Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation Nature 373 1995 444 448
9. J. O'Connell Role of Fas-FasL in inflammatory diseases Exp Rev Mol Med 10 2001 1 18
10. M.P. Boldin, T.M. Goncharov, Y.V. Goltsev, and D. Wallach Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor induced cell death Cell 86 1996 803 815
11. A.M. Chinnaiyan, K. O'Rourke, M. Tewari, and V.M. Dixit FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis Cell 81 1995 505 512
12. M. Enari, R.V. Talanian, W.W. Wong, and S. Nagata Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis Nature 380 1996 723 726
13. F.C. Kischkel, S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, and P.H. Krammer Cytotoxicity-dependent APO-1(Fas/CD95)-associated proteins from a death-inducing signaling complex (DISC) with the receptor EMBO J 14 1995 5579 5588
14. R.E. Ellis, J. Yuan, and H.R. Horvitz Mechanisms and functions of cell death Annu Rev Cell Biol 7 1991 663 698
15. S. Nagata Fas ligand-induced apoptosis Annu Rev Genet 33 1999 29 55
16. E.G. de Vries, T. Timmer, N.H. Mulder, C.M. Van Geelen, W.T. van der Graaf, and D.C. Spierings Modulation of death receptor pathways in oncology Drugs Today 39 Suppl C 2003 95 109
17. S. Yonehara Death receptor Fas and autoimmune disease: from the original generation to therapeutic application of agonistic anti-Fas monoclonal antibody Cytokine Growth Factor Rev 13 2002 393 402
18. J. Bajorath Identification of the ligand binding site in Fas (CD95) and analysis of Fas-ligand interactions Proteins 35 1999 475 482
19. J. Bajorath Analysis of Fas-ligand interactions using a molecular model of the receptor-ligand interface J Comput Aided Mol Des 13 1999 409 414
20. P. Schnedier, J.L. Bodmer, N. Holler, C. Mattmann, P. Scuderi, and A. Terskikh Characterization of Fas (Apo-1, CD95)-Fas ligand interaction J Biol Chem 272 1997 18827 18833
21. N.A. Kayagaki, T. Kawasaki, H. Ebata, S. Ohmoto, S. Ikeda, and K. Inoue Metallo-proteinase-mediated release of human Fas ligand J Exp Med 182 1995 1777 1783
22. M. Tanaka, T. Suda, T. Takahashi, and S. Nagata Expression of the functional soluble form of human Fas ligand in activated lymphocytes EMBO J 14 1995 1129 11335
23. K. Seino, K. Iwabuchi, N. Kayagaki, R. Miyata, I. Nagaoka, and A. Matsuzawa Chemotactic activity of soluble Fas ligand against phagocytes J Immunol 161 1998 4484 4488
24. K. Shudo, K. Kinoshita, R. Imamura, H. Fan, K. Hasumoto, and M. Tanaka The membrane-bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity Eur J Immunol 31 2001 2504 2511
25. S.J. Tang, K.H. Sun, G.H. Sun, T.Y. Chang, and G.C. Lee Recombinant expression of the Candida rugosa lip4 lipase in Escherichia coli Protein Exp Purif 20 2000 308 313
26. T. Mosmann Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
27. E.R. LaVallie, and J.M. McCoy Gene fusion expression systems in Escherichia coli Curr Opin Biotechnol 6 1995 501 506
28. M.L. Watson, P. D'Eustachio, B.A. Mock, A.D. Steinberg, H.C. Morse, and R.J. Oakey A linkage map of mouse chromosome 1 using an inter-specific cross segregation for the gld autoimmunity mutation Mamm Genome 2 1993 158 171
29. A.I. Derman, W.A. Prinz, D. Belin, and J. Beckwith Mutations that allow disulfide bond formation in the cytoplasm of Escherichia coli Science 262 1993 1744 1747
30. S.M. Mariani, B. Matiba, T. Sparna, and P.H. Krammer Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system J Immunol Methods 193 1996 63 70
31. L. Ottonello, G. Tortolina, M. Amelotti, and F. Dallegri Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes J Immunol 162 1999 3601 3606
32. J.R. Orlinick, K.B. Elkon, and M. Chao Separate domain of human Fas ligand dictate self-association and receptor binding J Biol Chem 272 1997 32222 32229
33. A. Marmenout, L. Fransen, J. Tavernier, J. Van der Heyden, R. Tizard, and E. Kawashima Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumor necrosis factor Eur J Biochem 152 1985 515 522
34. D. Pennica, J.S. Hayflick, T.S. Bringman, M.A. Palladino, and D.V. Goeddel Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor Proc Natl Acad Sci U S A 82 1985 6060 6064
35. H.J. Schoenfeld, B. Poeschl, J.R. Frey, H. Loetscher, W. Hunziker, and A. Lustig Efficient purification of recombinant human tumor necrosis factor beta from Escherichia coli yields biologically active protein with a trimeric structure that binds to both tumor necrosis factor receptors J Biol Chem 266 1991 3863 3869
36. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, and M. Kubin Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo Nat Med 5 1999 157 163
37. M. Tanaka, T. Itia, M. Adachi, and S. Nagata Downregulation of Fas ligand by shedding Nat Med 4 1998 31 36
38. B. Bader, K. Kuhn, D.J. Owen, H. Waldmann, A. Wittinghofer, and J. Kuhlmann Bioorganic synthesis of lipid-modified proteins for the study of signal transduction Nature 403 2000 223 226
39. K. Sankaran, and H.C. Wu Lipid modification of bacterial prolipoprotein transfer of diacylglyceryl moiety from phosphatidylglycerol J Biol Chem 296 1994 19701 19706